Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries GeneDx to Participate in Upcoming Investor Conferences in June By: GeneDx Holdings Corp. via GlobeNewswire May 24, 2023 at 16:05 PM EDT STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June: Jefferies Healthcare Conference Presentation on Wednesday, June 7, 2023, at 4:00 p.m. ET 44th Annual Goldman Sachs Global Healthcare Conference Fireside chat on Monday, June 12, 2023, at 12:20 p.m. ET (9:20 a.m. PT) A live and archived webcast of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDxGeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram. Investor Relations Contact:Tricia TruehartInvestors@GeneDx.com Media Contact:Maurissa MessierPress@GeneDx.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
GeneDx to Participate in Upcoming Investor Conferences in June By: GeneDx Holdings Corp. via GlobeNewswire May 24, 2023 at 16:05 PM EDT STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June: Jefferies Healthcare Conference Presentation on Wednesday, June 7, 2023, at 4:00 p.m. ET 44th Annual Goldman Sachs Global Healthcare Conference Fireside chat on Monday, June 12, 2023, at 12:20 p.m. ET (9:20 a.m. PT) A live and archived webcast of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDxGeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram. Investor Relations Contact:Tricia TruehartInvestors@GeneDx.com Media Contact:Maurissa MessierPress@GeneDx.com
STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that management will participate at the following investor conferences in June: Jefferies Healthcare Conference Presentation on Wednesday, June 7, 2023, at 4:00 p.m. ET 44th Annual Goldman Sachs Global Healthcare Conference Fireside chat on Monday, June 12, 2023, at 12:20 p.m. ET (9:20 a.m. PT) A live and archived webcast of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDxGeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram. Investor Relations Contact:Tricia TruehartInvestors@GeneDx.com Media Contact:Maurissa MessierPress@GeneDx.com